Skip to main content
. 2000 Jan 4;97(1):400–405. doi: 10.1073/pnas.97.1.400

Figure 4.

Figure 4

Lysis of the autologous melanoma UPCI-MEL 136.1 cells by anti-Melan-A/MART-151–73 CD4+ T cells derived from patient UPCI-MEL 136. CD4+ T cells were derived from the patient UPCI-MEL 136 after three rounds of in vitro stimulation with autologous DC pulsed with the Melan-A/MART-151–73 peptide, as previously described. The melanoma cells were preincubated for 48 h with IFN-γ before the lysis assay to up-regulate HLA-DR4 expression. T2.DR4 cells or Melan-A/MART-151–73 pulsed T2.DR4 (50,000/well) were added as cold-target inhibitors to suppress lysis. Chromium release was measured after 4 h. We show the data from one representative experiment of three performed. The effector-to-labeled target ratio was 60:1.